INTRODUCTION
Crohn's disease (CD) is a chronic relapsing inflammation of the gut, which causes significant impairment of quality of life with a rising incidence and prevalence during recent decades [1, 2] . Although the clinical manifestations and pathologic progress of CD are different, fibrosis of intes tinal organization and strictures induced by transmural inflammation will eventually cause intestinal obstruction, which is the characteristic clinical manifestation [35] . In addition, more than 1/3 of CD patients need at least one intestinal operation in their lives, while 70% of the CD patients with fibrosis strictures need partial resection of the intestinal tract within 10 years of disease progression, and 70%90% patients will have a recurrence of anas tomotic strictures and over 50% patients will form new strictures [6, 7] . Moreover, a large number of clinical and experimental results have confirmed that the main drugs for treatment of CD, such as glucocorticoids, immune agents and biological agents, can effectively inhibit intestinal inflammation, but do not have positive activity in preventing the further progress of intestinal fibrosis [8, 9] . Thus, there is still a lack of drugs that can effectively inhibit or reverse CD intestinal fibrosis.
The process of intestinal fibrosis in CD patients involves a variety of cells and multiple molecular signaling path ways [10, 11] . Due to the continuous role of chronic intestinal inflammation, activated T and B cells will produce large amounts of proinflammatory cytokines and profibro genic factors, and induce fibroblast, epithelial cells, en dothelial cells and stellate cells to migrate, proliferate, activate and differentiate into myofibroblasts, which finally results in excessive proliferation of myofibroblasts and excessive deposition of extracellular matrix (ECM), leading to the formation of intestinal fibrosis [1214] . Studies have shown that even if inflammation of the intestinal tract is effectively controlled, the process of fibrosis will continue and eventually lead to intestinal stenosis [15] . Epithelial to mesenchymal transition (EMT) plays an important role in the activation of fibroblasts [16] . Epithelial cells will lose epithelial polarity and epithelial phenotype contacted with basement membrane and produce fibro blasts to repair tissue injury caused by trauma and in flammatory reactions through the EMT progress [17] . In physiological states, when the inflammatory reaction is relieved, the transformation process stops sponta neously. However, in the case of continuous activation of the inflammatory reaction, the EMT process will also continue to exist, and eventually cause organ fibrosis. Under pathophysiologic conditions, when the inflamma tory reaction is relieved, the transformation process will stop spontaneously. However, in the case of continuous activation of inflammatory response, the EMT process will also exist continuously, and eventually cause organ fibrosis [18, 19] . Nowadays, although the role and regu lation mechanism of EMT in CD intestinal fibrosis has not been fully understood, the transforming growth factorβ (TGFβ)/Smad/MAPK signaling pathway has been confirmed to play an important role in regulating EMT in organs such as lung, liver, kidney and so on [2022] . Therefore, studying the role of EMT in the formation of intestinal fibrosis based on the TGFβ/Smad/MAPK signaling pathway, may provide a new target for the treatment of CD intestinal fibrosis.
Total flavone of Abelmoschus manihot L. Medic (TFA), as the main components of the water extract of traditional Chinese medicine Abelmoschus manihot (L.), has been reported to play an important role in the improvement of renal inflammation, nephrotic syndrome, purpura nephritis, IgA nephropathy, membranous ne phropathy and diabetic nephropathy (DN) effectively in the clinical trial [2326] . Further, our previous research has shown that TFA could significantly inhibit the re lease of the intestinal inflammatory cytokines tumor necrosis factor (TNF)α and interferon (IFN)γ in a CD rat model induced by 2,4,6trinitrobenzene sulfonic acid (TNBS), improve the model animal survival rate, and effectively improve intestinal inflammation. More over, immunohistochemical staining showed that the expression of TGFβ, alphasmooth muscle actin (αSMA) and matrix metalloproteinase2 (MMP2) were obviously reduced after intervention of TFA. Further, Masson staining confirmed that collagen fibrils of the mucosa and lamina propria of the colon were markedly decreased, indicating that TFA had positive inhibitory effects on CD intestinal fibrosis, which may be related to the EMT mechanism mediated by TGFβ. Thus, we hypothesized that TFA could inhibit or reverse the CD intestinal fibrosis via regulation of EMT based on TGFβ and its downstream Smad and MAPK signaling pathways. Therefore, this study was designed to focus on the influence of EMT on CD intestinal fibrosis and to further explore the role and mechanism of TFA on the progress of CD intestinal fibrosis.
MATERIALS AND METHODS

Preparation of TFA
Abelmoschus Manihot L. Medic was collected from Jiangyan of Jiangsu province, China. TFA was extracted from the flowers of Abelmoschus Manihot by the Jiangsu Province Hospital of TCM, Nanjing, China. A total of 500 g of Abelmoschus Manihot flowers was immersed in 8000 mL 75% ethanol for 1 h. The mixture was refluxed for 1 h at 90 ℃ and filtered by analytical filter paper. The extracts were evaporated by rotary evaporation under vacuum at 60 ℃ [27] . For cell experiments, TFA was dissolved in dimethyl sulfoxide.
Cell culture
Rat intestinal epithelial (IEC6) cells were obtained from the American Type Culture Collection (Manassas, VA, United States). Cells were cultured in Dulbecco's modified eagle's medium (DMEM, Gibco, United States) supplemented with 10% fetal bovine serum (FBS, Invitrogen, CA, United States), 2 mmol/L GlutaMAXI (Invitrogen, CA, United States), 100 U/mL penicillin, and 100 μg/mL streptomycin (Invitrogen) in 5% CO2 atmosphere at 37 ℃.
TFA working concentration
The concentration of TFA for further study was evaluated based on cell viability. Cell viability was determined by Cell Counting Kit8 assay (CCK8, Sigma Chemical Co, St Louis, MO, United States). Briefly, IEC6 cells with a density of 1 × 10 4 cells/well in 100 μL of complete culture medium were seeded in 96well plates. After culturing for 24 h, the medium was replaced with serumfree media or serumfree media containing TFA at concentrations ranging from 0.1 μg/mL to 50 μg/mL, and incubated in a humidified incubator at 37 ℃ for 24, 48 or 72 h. After incubation, 10 μL CCK8 was added to each well for 2 h at 37 ℃. The optical density (OD) was recorded at 450 nm using a microplate reader (Dojindo Molecular Technology, Rockville, MD, United States). Based on the results in Figure 1A , 5, 10, and 15 μg/ mL TFA represented the optimal working concentrations and were used in our subsequent experiments.
Gene silencing with siRNAs
Cells were transfected with nontargeting negative con trol siRNA (Dharmacon, Lafayette, CO, United States) or Smad2/3 (Dharmacon, Lafayette, CO, United States) using LipoRNAiMax according to the manufacturer's protocol. The cells were maintained for 72 h and then subjected to protein extraction. The antisense and sense oligo template sequences for these siRNAs were: Smad2 siRNA antisense: AAGAGGAGTGCGCTTATATTACCTGTCTC, sense: AATAATATAAGCGCACTCCTCCCTGTCTC; Smad3 siRNA antisense: AATATTCCAGAAACCCCACCCCCTGTCTC, sense: AAGGGTGGGGTT TCTGGAATACCTGTCTC.
Wound healing assay
IEC6 cells were seeded into 6well plates at a density of 6 × 10 5 cells per well, and were cultured in fresh culture media to full confluence. After that, we created a wound using a plastic scraper. After being washed with PBS, the medium was replaced with 10 ng/mL TGFβ1 [14] and were incubated overnight at 4 ℃ with the indicated antibodies. After incubation for 24 h, membranes were washed and incubated for 2 h at room temperature with corresponding secondary antibodies. For protein detection, membranes were developed with SuperSignal west femto maximum sensitivity substrate (Pierce, Rockford, IL, United States) and the GelPro Analyzer 6.0 software was applied for image analysis. Ecadherin (1:500), ZO1 (1:500), Vimentin (1:500), Ncadherin (1:500), pERK (1:500), ERK (1:500), pp38 (1:500), p38 (1:500), pJNK (1:500), JNK (1:500) and GAPDH (1:1000) antibodies were purchased from SigmaAldrich, and antimouse secondary antibodies were obtained from Proteintech (Chicago, IL, United States).
Immunofluorescence assay
IEC6 cells were plated into 6well plates at a density of 3 × 10 5 cells/mL. When cells reached 60% confluence, 10 ng/mL TGFβ1 and TFA (0, 5, 10 and 15 μg/mL) were added to the plates and incubated for 48 h. After that, IEC6 cells were fixed with 4% paraformaldehyde. After blocking cells with 3% BSA for 2 h at room temperature, the cells were incubated with the antiEcadherin (1:50) antibody or antiVimentin (1:50) antibody at room temperature for 2 h. After washing three times with PBS, the second antibody conjugated with FITC was incubated on these cells for 1 h at room temperature. The nuclei were counterstained with DAPI for 5 min. Cells were imaged using a Nikon Eclipse TE2000U fluorescence microscope.
Statistical analysis
Graph Pad Prism 5.0 statistical software was utilized to analyze the above experimental data. Measurement data were represented as X ± SD (n = 3); Oneway analysis of variance was applied to compare differences between multiple groups. When only two groups were compared, Student's ttest was conducted. A value of P < 0.05 indicated that the difference was statistically significant.
RESULTS
Effect of TFA on IEC-6 cell viability
In order to observe the effect of TFA on the EMT progress of IEC6 cells mediated by TGFβ1, a CCK8 assay was performed to assess the effect of TFA on the viability of IEC6 cells and to select the optimal concentrations of TFA for our further studies. IEC6 cells were treated with increasing concentrations of TFA ranging from 0.1 to 50 μg/mL at different time points (24, 48 and 72 h).
From the results of Figure 1 , we found that TFA had the positive activities on viability of IEC6 cells with the concentrations of 5, 10 and 15 μg/mL compared to the control group (TFA 0 μg/mL). Further, the TFAtreated group at 10 μg/mL displayed the maximum proliferative rate at 24, 48 and 72 h. Therefore, 5, 10 and 15 μg/mL TFA were chosen to be the optimal concentrations for our further studies.
Japan).
Trans-well invasion assay
The cell invasion assay was performed using Transwell chambers (8 μm poresize, Corning, United States). Matrigel was purchased from BD Biosciences and stored at 20 ℃. After thawing at 4 ℃ overnight, the matrigel was diluted in serumfree medium, and 30 μL of the diluted matrigel were evenly inoculated into the upper chamber to form a gel at 37 ℃. Cells (1 × 10 5 ) suspended in 300 μL of serumfree medium were seeded into the upper compartments and treated with 10 ng/mL TGFβ1 and TFA for 48 h, and the lower compartments were filled with 600 μL of medium with 20% FBS. After incubation, the noninvasive cells were removed from the upper surface of the membrane by scrubbing. The cells that invaded to the lower surface of the membrane were fixed with 4% paraformaldehyde and stained in 10% crystal violet. Cells were counted under a microscope (Olympus, Tokyo, Japan).
Real-time PCR analysis (qRT-PCR)
IEC6 cells were incubated in a 6well plate with a density of 6 
Western blotting assay
IEC6 cells were plated into 6well plates at a density of 3 × 10 5 cells/mL. When cells reached 60% con fluence, 10 ng/mL TGFβ1 and TFA (0, 5, 10 and 15 μg/mL) were added to the plates and incubated for 48 h. Each concentration group was performed in triplicate. Protein lysates were prepared using RIPA lysis buffer. Lysates were then subjected to SDSpoly acrylamide gel electrophoresis and transferred to PVDF membranes. After blocking with nonfat milk, blots
TFA inhibited TGF-β 1 induced migration and invasion of IEC-6 cells
The EMT process is characterized by alteration of cell morphology, migration and invasion capacity, as well as epithelial and mesenchymal markers expression. In the morphology assay, 10 ng/mL TGFβ1 in the me dium for 48 h led to significant morphological changes from cuboidal epithelial cells to fibroblastlike spindle shaped cells when compared with the control group. Interestingly, TFA effectively suppressed TGFβ1induced morphological changes of IEC6 cells in a dose dependent manner ( Figure 2A ). Moreover, for wound healing assays, 10 ng/ml TGFβ1 could promote the migration of IEC6 cells compared with the control group, while TFA obviously reduced the TGFβ1induced migration of IEC6 cells in a dose dependent manner ( Figure 2B ). In addition, we examined the effects of TFA on TGFβ1 induced invasion, and we found that 10 ng/mL TGFβ1 in the medium for 48 h induced IEC6 cells across the membrane, and addition of 5, 10 and 15 μg/mL TFA decreased the number of IEC6 cells that passed though the Matrigel ( Figure 2C ). The results indicated that TFA could significantly suppress the morphological change, migration and invasion of IEC6 cells induced by TGFβ1.
TFA inhibited TGF-β 1-induced EMT
To examine the alterations of EMT markers, as shown in Figure 3A , the expression of epithelial marker Ecadherin was decreased along with the increasing expression of the mesenchymal marker Vimentin after treatment with 10 ng/mL TGFβ1. However, TFA effectively inhibited this induction, especially at higher concentrations. Besides, western blotting and qRTPCR were carried out to exa mine the alterations of EMT markers, and we found that the protein levels of epithelial markers, including Ecadherin and ZO1, were markedly increased by TFA treatment. On the contrary, TFA treatment obviously decreased the expression levels of mesenchymal pro teins, including Vimentin and Ncadherin ( Figure 3B ). Likewise, similar changes were observed for mRNA 
TFA inhibited TGF-β 1-induced activation of the Smad signaling pathway
The activation of phosphorylated Smad2/3 plays an important role in the TGFβ1mediated EMT progress [28] . The status of the Smad pathways was determined in TGFβ1treated IEC6 cells following TFA treatment with the concentrations of 5, 10 and 15 μg/mL for 48 h, and the results have shown that TFA remarkably inhi bited the level of phosphorylated Smad 2/3 in a dose dependent manner ( Figure 4A ). Next, we examined the role of Smad in TGFβ1mediated IEC6 cells. In IEC6 cells, western blotting analysis demonstrated that Smad2/3 expression was inhibited after transfection of siSmad2/3 ( Figure 4B ). Moreover, our results revealed that siSmad2/3 could diminish TGFβ1triggered EMT in IEC6 cells and inhibit the TGFβ1elicited changes in the expression of EMT markers, as measured by western blotting and qRTPCR assays ( Figure 4B 
TFA inhibited TGF-β 1-induced activation of the nonSmad signaling pathway
In addition to the Smad2/3 signaling pathway, TGFβ has been reported to activate other signaling molecules, such as MAPKs, which include extracellular signal regulated kinase (ERK) 1/2, cJun NH2terminal kinase (JNK), and p38 mitogenactivated protein kinase (p38 MAPK) [29] . To explore the involvement of nonSmad signaling in the anti TGFβ1induced EMT activity of TFA, we tested whether TFA could inhibit the TGFβ1induced activation of p38, JNK and ERK1/2 by western blotting, and we found that TGFβ1 could significantly activate the expressions of pp38, pJNK and pERK1/2, while TFA at the concentrations of 5, 10 and 15 μg/mL obviously suppressed the TGFβ1induced increase in pp38, pJNK and pERK1/2 levels in IEC6 cells in a dose dependent manner ( Figure 6A ). Thus, in order to further explore the role of MAPKs in TGFβ1treated IEC6 cells, ERK1/2 inhibitor (PD98059, 5 μmol/L), p38 inhibitor (SB203580, 5 μmol/L) and JNK inhibitor (SP600125, 2 μmol/L) were used to treat IEC6 cells mediated by TGFβ1. From the results in Figure 6A , we found that PD98059, SB203580 and SP600125 could significantly inhibit the activation of pp38, pJNK and pERK, respectively. Besides, PD98059, SB203580 and SP600125 could promote the changes in EMT markers by western blotting and qRTPCR assays ( Figure 6B and C) . In addition, PD98059, SB203580 and SP600125 treatment inhibited TGFβ1induced men senchymallike morphological changes in IEC6 cells, as shown in Figure 7A . Moreover, PD98059, SB203580 and SP600125 inhibited the migration and invasion of IEC6 cells mediated by TGFβ1 via wound healing and trans well assays ( Figure 7B and C) . Importantly, cotreatment of TFA with PD98059, SB203580 or SP600125 had better inhibitory effects on TGFβ1induced EMT in IEC6 cells than either one of them. Taken together, these results indicated that TFA might exert its role in reversing TGF β1mediated EMT via nonSmad inactivation in IEC6 cells.
DISCUSSION
CD intestinal fibrosis is characterized by activation of myofibroblasts, resulting in abnormal ECM deposition, which eventually leads to tissue stiffness and progressive intestinal dysfunction [30] . In addition to interstitial cells such as fibroblasts and smooth muscle cells, the diffe rentiation of epithelial cells through EMT is a major source of intestinal fibrotic cells [18] . EMT refers to the transformation of epithelial cells with polar cells to the interstitial cells under a specific physiological and pathological condition. The most important features of EMT are the loss of epithelial cell phenotype and the acquisition of interstitial properties, as reflected in the downregulation of Ecadherin and ZO1, resulting in loss of adhesion between cells or between cells and matrix, overexpression of Ncadherin and vimentin, leading to the acquisition of migration and invasion, and overexpression of EMT transcription factors [31, 32] . More over, EMT plays a key role in tissue formation, organ fibrosis and so on. Through EMT, epithelial cells lose cell polarity and epithelial phenotypes, such as connection to the basement membrane, while acquiring interstitial cell phenotypes with the functions of fibroblasts and myofibroblasts [3335] . Moreover, in the case of continuous activation of inflammatory response, the EMT process will also continuously exist and eventually cause organ fibrosis. Therefore, it will have a positive significance to search for a method for the treatment of CD intestinal fibrosis.
Our previous studies have found that TFA, a main component of the water extract of traditional Chinese medicine, could reduce the expression of TGFβ, αSMA and MMP2 and decrease collagen fibrils, which indi
Smad2/3 control TGF-β1
TFA + si-Smad2/3 TFA Control Figure 5 Total flavone of Abelmoschus manihot (TFA) combined with si-Smad2/3 had synergistic role in inhibiting transforming growth factor-β1-induced migration and invasion of IEC-6 cells. A: The inhibitory effect of si-Smad or TFA (15 μg/mL) combined with si-Smad2/3 on TGF-β1-induced morphological changes at 48 h was observed by phase contrast microscopy; B and C: The migration and invasion abilities of si-Smad or TFA (15 μg/mL) combined with si-Smad2/3 were examined by wound healing (B) and transwell (C) assays. TFA: Total flavone of Abelmoschus manihot; TGF: Transforming growth factor.a cated that TFA may inhibit or reverse EMT during CD intestinal fibrosis. Firstly, we used TGFβ1 to induce EMT of IEC6 cells and chose the optimal concentrations of TFA to disrupt TGFβ1 activity in IEC6 cells. From the results, we knew that TGFβ1 could obviously promote the progression of EMT, such as changing morphology from cuboidal epithelial cells to fibroblastlike spindle shaped cells, and enhancing the abilities of migration and invasion. Despite this, TFA treatment could restrain the changes caused by TGFβ1 in a dose dependent manner.
Effective inhibition of CD intestinal inflammation does not play a positive role in preventing intestinal fibrosis and inhibiting the profibrosis signaling pathway, resulting in persistence of the process of tissue fibrosis [36, 37] . Therefore, it is necessary to further study how to block the fibrotic signaling pathway and promote ECM decom position to inhibit or reverse the process of fibrosis. TGFβ is the strongest inducer, playing an important role in EMT [38] . The Smad signaling pathway induced by TGFβ can promote the expression of ECM and inhi bit the transcriptional activity of matrix degradation genes, resulting in ECM deposition in interstitial cells and leading to fibrosis [39] . Actually, in our experiments, we found that 10 ng/mL TGFβ1 could significantly inhibit the expression of pSmad2/3, while TFA remarkably reversed the phenomenon in a dose dependent manner in TGFβ1treated IEC6 cells. Blocking TGFβ/Smad signaling has become a hot spot to inhibit or even re verse fibrosis. It has been reported that silencing Smad 2/3 could block Smad signaling and reduce collagen synthesis and proliferation of fibroblasts [40, 41] . We silenced the expression of pSmad2/3 and explored the role of Smad2/3 in TGFβ1treated IEC6 cells. We found that silencing Smad2/3 could effectively improve the EMT progression of IEC6 cells induced by TGFβ1 no matter morphology, migration, invasion or EMT markers. Interestingly, when TFA was combined with siSmad2/3, it had better inhibitory activities on EMT progression than either one of them alone, which suggested that TFA might exert its effects in reversing TGFβ1mediated EMT via Smad inactivation in IEC6 cells.
Recent researches have shown that the MAPK path way, including p38, JNK and ERK1/2, is closely related to the regulation of TGFβ signaling pathway and fibrosis [42] . TGFβ can not only carry out signal transduction through TGFβ/Smad, but can also activate p38, JNK and ERK signaling pathways, which indicates that regulation of MAPK signaling pathways can affect the TGFβ/Smad signal transduction pathway and play a role in inhibiting fibrosis [43, 44] . In this experiment, we found that 10 ng/mL TGFβ1 could significantly inhibit the expression of pp38, pJNK and pERK1/2, while TFA obviously suppressed the levels in a dose dependent manner in TGFβ1treated IEC6 cells. In addition, we also investigated the role of MAPK in TGFβ1mediated EMT of IEC6 cells. We used an ERK1/2 inhibitor (PD98059), p38 inhibitor (SB203580) and JNK inhibitor (SP600125) to inhibit the expression of pp38, pJNK and pERK1/2 in IEC6 cells, respectively. We found that PD98059, SB203580 and SP600125 treatment could have positive inhibitory effects on EMT progress, similar to the siSmad. Moreover, cotreatment of TFA combined with PD98059, SB203580 or SP600125 had better positive activities on inhibiting EMT progress in TGFβ1mediated IEC6 cells than either one of them alone, indicating that TFA might exert its role in reversing EMT induced by TGFβ1 via MAPK inactivation in IEC6 cells. 
ARTICLE HIGHLIGHTS
Research background
Epithelial-mesenchymal transition (EMT) is a crucial process in Crohn's disease (CD) intestinal fibrosis. Total flavone of Abelmoschus manihot (TFA) has been found as an effective component to reduce CD intestinal fibrosis in vivo. However, the role and mechanism of TFA on EMT progress of CD intestinal fibrosis have not been understood yet.
Research motivation
EMT is a crucial process in CD intestinal fibrosis. TFA has been found as an effective component to reduce CD intestinal fibrosis in vivo. However, the role and mechanism of TFA on EMT progress of CD intestinal fibrosis have not been understood yet. In the present study, we performed CCK-8, morphology, wound 
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healing, transwell, qRT-PCR, western blotting and immunofluorescence assays to explore the role and the underlying mechanisms of TFA on CD intestinal fibrosis, and the results indicated that TFA was expected to advance as a new therapy to treat CD intestinal fibrosis.
Research objectives
To explore the role and mechanism of TFA on EMT progress of CD intestinal fibrosis.
Research methods
First, a CCK-8 assay was performed to assess the effect of TFA on the viability of IEC-6 cells and to select the optimal concentrations of TFA for our further studies. Then cell morphology, wound healing and transwell assays were performed to examine the effect of TFA on morphology, migration and invasion of IEC-6 cells treated with transforming growth factor-β1 (TGF-β1). In addition, immunofluorescence, qRT-PCR and western blotting assays were carried out to detect the impact of TFA on EMT progress. Moreover, western blotting assay was performed to evaluate the function of TFA on the Smad and MAPK signaling pathways. Further, the role of co-treatment of TFA and si-Smad or MAPK inhibitors was examined by qRT-PCR, western blotting, morphology, wound healing and transwell assays.
Research results
In this study, TFA promoted TGF-β1-induced IEC-6 cell morphological change, migration and invasion, and increased the expression of epithelial markers and reduced the levels of mesenchymal markers, along with the inactivation of Smad and MAPK signaling pathways. Moreover, we revealed that si-Smad and MAPK inhibitors effectively attenuated TGF-β1-induced EMT in TEC-6 cells. Importantly, co-treatment of TFA and si-Smad or MAPK inhibitors had better inhibitory effects on TGF-β1-induced EMT in IEC-6 cells than either one of them alone.
Research conclusions
These findings could provide new insight into the molecular mechanisms of TFA on TGF-β1-induced EMT in IEC-6 cells, and TFA is expected to advance as a new therapy to treat CD intestinal fibrosis.
Research perspectives
TFA promoted the induction of EMT partly by inhibiting TGF-β1-activated Smad signaling pathway and non-Smad signaling pathway. TFA is expected to advance as a new therapy to treat CD intestinal fibrosis, and its continued advancement may open the door to a new class of treatment for CD intestinal fibrosis.
